Tags : Paratek

PharmaShots Weekly Snapshot (February 24-28, 2020)

1. Companion Medical’s InPen Diabetes Management System Receives the US FDA’s Approval for Fixed Dosing and Meal Estimation Published: Feb 28, 2020 | Tags: Companion Medical, InPen Diabetes Management System, Receives, US, FDA, Approval, Fixed Dosing, Meal Estimation 2.  Takeda’s Vedolizumab SC Receives CHMP’s Positive Opinion as a Maintenance Therapy for Moderately to Severely Active […]Read More

Paratek’s Reports Results of Nuzyra (Omadacycline) in P-III OPTIC and

Shots: The P-III OPTIC and OASIS-1 studies involves assessing of Nuzyra (Omadacycline) vs moxifloxacin & linezolid in 386 & 645 patients with community acquired bacterial pneumonia (CABP) & acute bacterial skin and skin structure infections (ABSSSI) respectively OPTIC study results: ECR (81.1, vs 82.7%,); IACR @PTE (87.6%, vs 85.1%); TEAEs (6.0% vs 6.7%); OASIS-1 study: […]Read More